Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Escudier, Bernard; Grunwald, Viktor; Ravaud, Alain; Ou, Yen-Chuan; Castellano, Daniel; Lin, Chia-Chi; Gschwend, Jurgen E; Harzstark, Andrea; Beall, Sarah; Pirotta, Nicoletta; Squires, Matthew; Shi, Michael M; Angevin, Eric 
Titel:
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. 
Abstract:
Fibroblast growth factor (FGF) signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGF receptor (VEGFR) inhibitors. Dovitinib (TKI258) is a tyrosine kinase inhibitor (TKI) that inhibits FGF receptor (FGFR), VEGFR, and platelet-derived growth factor receptor, which are known drivers of antiangiogenic escape, angiogenesis, and tumor growth in renal cell carcinoma (RCC).Patients with advanced or metastatic RCC were treated with oral dovitinib 500 mg/...    »
 
Zeitschriftentitel:
Clin Cancer Res 
Jahr:
2014 
Band / Volume:
20 
Heft / Issue:
11 
Seitenangaben Beitrag:
3012-22 
Sprache:
eng 
Print-ISSN:
1078-0432 
TUM Einrichtung:
Urologische Klinik und Poliklinik